Chia Tai Tianqing launched a Phase III trial (NCT pending) on 4 July for TQB2930, its HER2 bispecific antibody (BsAb), in HER2-positive advanced breast cancer patients who failed ≥2 prior anti-HER2 therapies. The randomised, open-label study (n=estimated 300) compares TQB2930 plus chemotherapy versus trastuzumab plus chemotherapy, with independent review committee-assessed progression-free survival (PFS) as the primary endpoint.

TQB2930 uniquely binds both HER2 extracellular domains (ECD2 and ECD4), mimicking the mechanisms of pertuzumab and trastuzumab. It joins a competitive global HER2 bispecific landscape dominated by BeiGene/Jazz's zanidatamab (the only approved drug in class) and Alphamab/CSPC's anbenitamab (also in Phase III). Chia Tai Tianqing's candidate aims to address late-line treatment resistance with improved target engagement.